{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Recurrence&page=2",
    "query": {
      "condition": "Cancer Recurrence",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Recurrence&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T07:45:25.496Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05362409",
      "title": "Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Grade Glioma"
      ],
      "interventions": [
        {
          "name": "5 Aminolevulinic Acid",
          "type": "DRUG"
        },
        {
          "name": "CV01-delivered ultrasound",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Alpheus Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2022-06-29",
      "completion_date": "2025-02-03",
      "has_results": false,
      "last_update_posted_date": "2025-06-19",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Amherst, New York • Lake Success, New York",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Amherst",
          "state": "New York"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05362409"
    },
    {
      "nct_id": "NCT05183204",
      "title": "Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Paxalisib",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Ketogenic Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2022-02-14",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05183204"
    },
    {
      "nct_id": "NCT02159989",
      "title": "Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Fibrolamellar Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Ovarian Carcinoma",
        "Pancreatic Neuroendocrine Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Refractory Malignant Solid Neoplasm",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "Ziv-Aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2014-06-18",
      "completion_date": "2024-01-29",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02159989"
    },
    {
      "nct_id": "NCT00002616",
      "title": "Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "Up to 64 Years"
      },
      "enrollment_count": 36,
      "start_date": "1995-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002616"
    },
    {
      "nct_id": "NCT05222984",
      "title": "Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Navitoclax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2022-07-29",
      "completion_date": "2027-03-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05222984"
    },
    {
      "nct_id": "NCT01800838",
      "title": "Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage IA Mycosis Fungoides/Sezary Syndrome",
        "Stage IB Mycosis Fungoides/Sezary Syndrome",
        "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage IIA Mycosis Fungoides/Sezary Syndrome"
      ],
      "interventions": [
        {
          "name": "silicon phthalocyanine 4",
          "type": "DRUG"
        },
        {
          "name": "photodynamic therapy",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kevin Cooper MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-04",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2019-05-16",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01800838"
    },
    {
      "nct_id": "NCT00311558",
      "title": "Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sodium stibogluconate",
          "type": "DRUG"
        },
        {
          "name": "SSG & interferon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 18,
      "start_date": "2005-10",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2018-01-26",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00311558"
    },
    {
      "nct_id": "NCT00555048",
      "title": "Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "Up to 50 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-05-24",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00555048"
    },
    {
      "nct_id": "NCT05883449",
      "title": "Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Hodgkin Lymphoma",
        "Peripheral T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "AFM13",
          "type": "DRUG"
        },
        {
          "name": "AB-101",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Affimed GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2023-10-10",
      "completion_date": "2025-06-13",
      "has_results": true,
      "last_update_posted_date": "2025-08-20",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05883449"
    },
    {
      "nct_id": "NCT02476955",
      "title": "Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Ovarian Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "ARQ 092 + carboplatin + paclitaxel (Closed)",
          "type": "DRUG"
        },
        {
          "name": "ARQ 092 + paclitaxel (Closed)",
          "type": "DRUG"
        },
        {
          "name": "ARQ 092 + anastrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2015-06-09",
      "completion_date": "2019-05-07",
      "has_results": false,
      "last_update_posted_date": "2020-09-30",
      "last_synced_at": "2026-07-22T07:45:25.496Z",
      "location_count": 5,
      "location_summary": "Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02476955"
    }
  ]
}